224
Participants
Start Date
October 31, 2006
Primary Completion Date
December 31, 2009
Study Completion Date
December 31, 2009
Omalizumab
Subcutaneous injections of omalizumab will be administered every 2 or 4 weeks along with standardized asthma care for 60 weeks, beginning with the Randomization Visit, as a part of ICATA (ICAC-08, NCTNCT00377572).
Mount Sinai School of Medicine, New York
Rainbow Babies and Children's Hospital, Cleveland
Children's Memorial Hospital, Chicago
University of Texas Southwestern Medical Center, Dallas
National Institute of Allergy and Infectious Diseases (NIAID)
NIH